Zoetis (ZTS)

Stocks slipped Tuesday as fresh economic data reignited stagflation fears on Wall Street, overshadowing a blowout quarter from Palantir Technologies Inc.

Zoetis beats Q2 estimates with strong pet product sales and raises full-year guidance despite livestock sales decline and Librela weakness.

The company raised its adjusted profit guidance by 10 cents at the midpoint and hiked its sales guide by $25 million.

Animal health company Zoetis (NYSE:ZTS) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 4.2% year on year to $2.46 billion. The company expects the full year’s revenue to be around $9.53 billion, close to analysts’ estimates. Its non-GAAP profit of $1.76 per share was 9.2% above analysts’ consensus estimates.

Stay updated with the S&P500 stocks that are on the move in today's pre-market session.

The demand for this company's products will continue increasing.

IDEXX Laboratories (NASDAQ: IDXX), a global leader in veterinary diagnostics and software, has sent ripples through the financial markets with an astounding 27.5% surge in its stock price. This remarkable leap was ignited by the company's stellar second-quarter earnings report, which not only shattered Wall Street's profit and sales

Animal health company Zoetis (NYSE:ZTS) will be announcing earnings results this Tuesday morning. Here’s what to expect.

The "Warren Buffett of Britain" dumped Buffett's actual No. 1 holding in favor a stock with the legs to run higher.

Over the last six months, Zoetis’s shares have sunk to $153.39, producing a disappointing 11.4% loss - a stark contrast to the S&P 500’s 5.8% gain. This may have investors wondering how to approach the situation.

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Zoetis (NYSE:ZTS) and its peers.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Bristol-Myers Squibb (NYSE:BMY) and the best and worst performers in the branded pharmaceuticals industry.

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.

Phibro Animal Health gains JPMorgan upgrade as analyst forecasts continued growth across key livestock products and long-term fundamentals.

By avoiding big swings, low-volatility stocks let investors focus on long-term fundamentals. These stocks may not be up 100% in a single year, but they offer a measured approach to building wealth over time.

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.

Elanco upgraded to Outperform by William Blair as pipeline gains traction and EMA backs Zenrelia ahead of expected Q3 approval.

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.